npca-annual-report-2021

In the 2021 Annual Report, we present the results for patients diagnosed between 1st April 2019 and 31st March 2020 in England and Wales including: 1. The participation of NHS providers and the completeness and quality of the data submitted to the National Cancer Registration and Analysis Service (NCRAS), Public Health England and the Wales Cancer Network, Public Health Wales. 2. Patient demographic information and key aspects of the diagnostic and staging process they underwent and the treatments they received . 3. Treatment outcomes (up to two years post-treatment) for men in England and Wales undergoing radical prostatectomy (RP) or radical external beam radiotherapy (EBRT) in 2018. 4. The variation in treatment for men with low-risk, localised disease and high-risk/locally advanced disease in Wales only. In addition, we also present: 5. The impact of COVID-19 on the diagnosis of prostate cancer, receipt of radical treatment and systemic therapy in England only. Individual provider results and reports are available enabling regional and national comparisons to support local QI. https://www.npca.org.uk/provider-results/本2021年度报告呈现了2019年4月1日至2020年3月31日期间英格兰与威尔士地区确诊患者的相关研究结果，具体涵盖以下内容： 1. 英国国民保健服务（NHS）医疗机构的参与情况，以及提交至国家癌症登记与分析服务处（National Cancer Registration and Analysis Service, NCRAS）、英国公共卫生署（Public Health England）以及威尔士癌症网络（Wales Cancer Network）、威尔士公共卫生署（Public Health Wales）的相关数据的完整性与质量。 2. 患者的人口统计学信息，以及其接受的诊断、分期流程与治疗方案的关键环节。 3. 2018年英格兰与威尔士地区接受根治性前列腺切除术（radical prostatectomy, RP）或根治性体外放射治疗（radical external beam radiotherapy, EBRT）的男性患者的治疗结局（随访至治疗后两年）。 4. 仅针对威尔士地区，低风险局限性前列腺癌患者与高风险/局部晚期前列腺癌患者的治疗方案差异情况。 此外，本报告还涵盖： 5. 仅针对英格兰地区，新型冠状病毒肺炎（COVID-19）对前列腺癌诊断、根治性治疗与系统治疗的影响。 本报告提供各医疗机构的单项结果与专项报告，可支持开展区域及全国层面的对比分析，以助力本地质量改进工作。相关链接：https://www.npca.org.uk/provider-results/